[go: up one dir, main page]

WO2001051523A3 - Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation - Google Patents

Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation Download PDF

Info

Publication number
WO2001051523A3
WO2001051523A3 PCT/US2001/000565 US0100565W WO0151523A3 WO 2001051523 A3 WO2001051523 A3 WO 2001051523A3 US 0100565 W US0100565 W US 0100565W WO 0151523 A3 WO0151523 A3 WO 0151523A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragments
methods
angiogenic proteins
proteins
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/000565
Other languages
English (en)
Other versions
WO2001051523A2 (fr
Inventor
Raghuram Kalluri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/625,191 external-priority patent/US6962974B1/en
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Priority to JP2001551107A priority Critical patent/JP2003519630A/ja
Priority to CA002396235A priority patent/CA2396235A1/fr
Priority to EP01900949A priority patent/EP1337633A2/fr
Priority to AU26356/01A priority patent/AU783662B2/en
Publication of WO2001051523A2 publication Critical patent/WO2001051523A2/fr
Priority to US10/032,221 priority patent/US7387779B2/en
Anticipated expiration legal-status Critical
Publication of WO2001051523A3 publication Critical patent/WO2001051523A3/fr
Priority to AU2006200751A priority patent/AU2006200751A1/en
Priority to US12/127,193 priority patent/US20090054344A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des protéines et des fragments de celles-ci possédant des propriétés anti-angiogéniques, ainsi que des méthodes d'utilisation de ces protéines et de ces fragments permettant d'inhiber ou de promouvoir l'angiogénèse.
PCT/US2001/000565 1998-06-17 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation Ceased WO2001051523A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2001551107A JP2003519630A (ja) 2000-01-07 2001-01-08 抗血管新生タンパク質およびその断片ならびに使用方法
CA002396235A CA2396235A1 (fr) 2000-01-07 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
EP01900949A EP1337633A2 (fr) 2000-01-07 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
AU26356/01A AU783662B2 (en) 2000-01-07 2001-01-08 Anti-angiogenic proteins and fragments and methods of use thereof
US10/032,221 US7387779B2 (en) 1998-06-17 2001-12-21 Anti-angiogenic proteins and fragments and methods of use thereof
AU2006200751A AU2006200751A1 (en) 2000-01-07 2006-02-23 Anti-Angiogenic Proteins and Fragments and Methods of Use Thereof
US12/127,193 US20090054344A1 (en) 1998-06-17 2008-05-27 Anti-angiogenic proteins and fragments and methods of use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47911800A 2000-01-07 2000-01-07
US09/479,118 2000-01-07
US54337100A 2000-04-04 2000-04-04
US09/543,371 2000-04-04
US09/625,191 US6962974B1 (en) 1998-06-17 2000-07-21 Anti-angiogenic proteins and fragments and methods of use thereof
US09/625,191 2000-07-21

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US47911800A Continuation-In-Part 1998-06-17 2000-01-07
US54337100A Continuation-In-Part 1998-06-17 2000-04-04
US09/625,191 Continuation-In-Part US6962974B1 (en) 1998-06-17 2000-07-21 Anti-angiogenic proteins and fragments and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/032,221 Continuation-In-Part US7387779B2 (en) 1998-06-17 2001-12-21 Anti-angiogenic proteins and fragments and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2001051523A2 WO2001051523A2 (fr) 2001-07-19
WO2001051523A3 true WO2001051523A3 (fr) 2002-08-08

Family

ID=27413473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000565 Ceased WO2001051523A2 (fr) 1998-06-17 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation

Country Status (6)

Country Link
EP (1) EP1337633A2 (fr)
JP (1) JP2003519630A (fr)
CN (1) CN1420926A (fr)
AU (2) AU783662B2 (fr)
CA (1) CA2396235A1 (fr)
WO (1) WO2001051523A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
AU1182402A (en) * 2000-10-02 2002-04-15 Scripps Research Inst Methods and compositions for enhancing angiogenesis
CA2451942A1 (fr) 2001-07-27 2003-02-13 Munirathinam Sundaramoorthy Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv
WO2003093303A1 (fr) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic
WO2004067762A2 (fr) * 2003-01-27 2004-08-12 University Of Kansas Medical Center Structure cristallisee hexamere a domaine nc1 de collagene de type iv
JP4843767B2 (ja) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 がん細胞特異的遺伝子発現法を用いた血管新生阻害薬
ATE551067T1 (de) 2006-02-03 2012-04-15 Crc For Asthma And Airways Ltd Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen
FR2898895B1 (fr) * 2006-03-23 2012-04-06 Univ Reims Champagne Ardenne Cyclopeptide a activite anti-cancereuse derive du collagene de type iv
US9056923B2 (en) 2010-12-10 2015-06-16 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphagiogenesis-dependent diseases
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
GB201721387D0 (en) * 2017-12-20 2018-01-31 Nordic Bioscience As Tumstatin assay
CN113735966B (zh) * 2021-09-29 2022-11-01 陕西巨子生物技术有限公司 一种抗肿瘤重组胶原蛋白及其制备方法和应用
CN114931665B (zh) * 2021-12-14 2024-09-27 广州医科大学 六型胶原α2亚基在神经修复产品中的应用
CN117720619B (zh) * 2023-05-16 2024-10-29 杭州禾泰健宇生物科技有限公司 一种多肽、抗光老化多肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049885A2 (fr) * 1998-03-27 1999-10-07 University Of Kansas Medical Center Utilisation de domaines isoles de collagene du type iv pour modifier des interactions cellulaires et tissulaires
WO1999065940A1 (fr) * 1998-06-17 1999-12-23 Beth Israel Deaconess Medical Center Proteines anti-angiogeniques et methodes d'utilisation de ces proteines
WO2000059532A1 (fr) * 1999-04-01 2000-10-12 Biostratum, Inc. Utilisation de domaine de collagene de type iv permettant d'inhiber l'angiogenese et la croissance tumorale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049885A2 (fr) * 1998-03-27 1999-10-07 University Of Kansas Medical Center Utilisation de domaines isoles de collagene du type iv pour modifier des interactions cellulaires et tissulaires
WO1999065940A1 (fr) * 1998-06-17 1999-12-23 Beth Israel Deaconess Medical Center Proteines anti-angiogeniques et methodes d'utilisation de ces proteines
WO2000059532A1 (fr) * 1999-04-01 2000-10-12 Biostratum, Inc. Utilisation de domaine de collagene de type iv permettant d'inhiber l'angiogenese et la croissance tumorale

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COLORADO P.C. ET AL.: "Anti-angiogenic cues from vascular basement membrane Collagen", CANCER RESEARCH, vol. 60, 1 May 2000 (2000-05-01), pages 2520 - 2526, XP001019102 *
COLORADO P.C. ET AL.: "Arresten: Angiogenesis and Renal Cell Carcinoma Tumor Inhibiting Matrix Protein", J. OF THE AMERICAN SOC. OF NEPHROLOGY, vol. 10, 1999, pages 489A, XP001018558 *
HAN J ET AL: "A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 33, 15 August 1997 (1997-08-15), pages 20395 - 20401, XP002118639, ISSN: 0021-9258 *
J.A. VARNER: "The Role of Vascular Integrins alpha v beta 3 and alpha v beta 5 in angiogenesis", 1997, BIRKHÄUSER, BASEL, XP002924175 *
KAMPHAUS G.D. ET AL.: "Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth", J. BIOL. CHEM., vol. 275, no. 2, 14 January 2000 (2000-01-14), pages 1209 - 1215, XP002177916 *
KAMPHAUS G.D. ET AL.: "Canstatin: A novel matrix derived inhibitor of Angiogenesis and Renal Cell Carcinoma", J. OF THE AMERICAN SOC. OF NEPHROLOGY, vol. 10, 1999, pages 495A, XP001018557 *
KEFALIDES N A ET AL: "SUPPRESSION OF TUMOR CELL GROWTH BY TYPE IV COLLAGEN AND A PEPTIDE FROM THE NC1 DOMAIN OF THE ALPAH3(IV) CHAIN", MEDICINA, BUENOS AIRES, AR, vol. 59, no. 5-2, 1999, pages 553, XP002144122, ISSN: 0025-7680 *
MAESHIMA Y. ET AL.: "Two RGD-independent alpha v beta 3 Integrin binding sites on Tumstatin regulate Distinct anti-tumor properties", J. BIOL. CHEM., vol. 275, no. 31, 4 August 2000 (2000-08-04), pages 23745 - 23750, XP002177918 *
NICKOLS A ET AL: "ANTIANGIOGENIC AND ANTICANCER ACTIVITIES OF ANTAGONISTS OF INTEGRINALPHAVBETA3", PROCEEDINGS OF THE 88TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN DIEGO, APR. 12 - 16, 1997, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, AACR, US, vol. 38, 1 March 1997 (1997-03-01), pages 206, XP002071773 *
PETITCLERC ET AL.: "New functions for non-collagenous domains of human collagen type IV", J. BIOL. CHEM., vol. 275, no. 11, 17 March 2000 (2000-03-17), pages 8051 - 8061, XP002144125 *
PRESTAYKO ET AL: "Type IV collagen domains inhibit adhesion and migration of tumor cells and block angiogenesis", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, 28 March 1998 (1998-03-28), pages 45, XP002118641 *

Also Published As

Publication number Publication date
WO2001051523A2 (fr) 2001-07-19
CN1420926A (zh) 2003-05-28
EP1337633A2 (fr) 2003-08-27
AU2006200751A1 (en) 2006-03-16
AU783662B2 (en) 2005-11-24
AU2635601A (en) 2001-07-24
CA2396235A1 (fr) 2001-07-19
JP2003519630A (ja) 2003-06-24

Similar Documents

Publication Publication Date Title
WO2001051523A3 (fr) Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
GEP20105118B (en) Anti-vegf antibodies
TR200100056T2 (tr) Nörotrofik faktörler
BR9813569B1 (pt) processo, e, composiÇço de aditivo alimentÍcio.
AU3700400A (en) Frozen chlorine dioxide-containing composition and methods related thereto
WO2005016455A3 (fr) Anticorps variables
AU2002365258A1 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
AU2002231961A1 (en) Detectable compositions, methods of forming the same and detection techniques
ID28345A (id) Komposisi untuk digunakan dalam pengubahan hidrokarbon, pembuatan dan penggunaannya
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
CA95794S (en) Paving stone
AU2002219960A1 (en) Molecules of the card-related protein family and uses thereof
WO2002044360A3 (fr) Arginine deiminase modifiee
WO2004031352A3 (fr) Variants d'interferons presentant des proprietes ameliorees
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2002225247A1 (en) The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
DE69824198D1 (de) Verbesserung der geschmackseigenschaften von vergorenen getränken
AU2003295050A1 (en) Method for enhancing the physico-chemical properties of bitumen compositions and novel bitumen compositions with enhanced properties and their uses
WO2001043067A3 (fr) Ameliorations relatives a des applications des techniques fractales et/ou chaotiques
WO2001066752A3 (fr) Genes specifiques de la reproduction
WO2001088137A3 (fr) Proteines du type proteine adaptatrice myd88
AU2002228957A1 (en) Molecular electro-optical switching or memory device, and method of making the same
WO2001058954A3 (fr) Molecules trade et utilisations associees a ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 26356/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2396235

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 551107

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001900949

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 018050506

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001900949

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 26356/01

Country of ref document: AU